Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125596021 | 12559602 | 1 | I | 20150710 | 0 | 20160714 | 20160714 | DIR | 36.00 | YR | M | N | 200.00000 | LBS | 20160713 | N | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125596021 | 12559602 | 1 | PS | FINASTERIDE. | FINASTERIDE | 1 | Oral | Y | Y | 0 | QD | ||||||||
| 125596021 | 12559602 | 3 | C | ADDERALL | AMPHETAMINE ASPARTATEAMPHETAMINE SULFATEDEXTROAMPHETAMINE SACCHARATEDEXTROAMPHETAMINE SULFATE | 1 | 0 | ||||||||||||
| 125596021 | 12559602 | 5 | C | MIRTAZAPINE. | MIRTAZAPINE | 1 | 0 | ||||||||||||
| 125596021 | 12559602 | 7 | C | SERTRALINE | SERTRALINE HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125596021 | 12559602 | 1 | Androgenetic alopecia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125596021 | 12559602 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125596021 | 12559602 | Erectile dysfunction | |
| 125596021 | 12559602 | Gynaecomastia | |
| 125596021 | 12559602 | Libido decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125596021 | 12559602 | 1 | 20150301 | 20160713 | 0 |